Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Fulvestrant 500 mg|DRUG: Exemestane 25 mg
Sponsor: Chinese Academy of Medical Sciences
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences